H. Mahrholdt, A. Wagner, C. C. Deluigi, E. Kispert, S. Hager et al., Presentation, patterns of myocardial damage, and clinical course of viral myocarditis, Circulation, vol.114, issue.15, pp.1581-90, 2006.

L. T. Cooper, K. L. Baughman, A. M. Feldman, A. Frustaci, M. Jessup et al., The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology, J Am Coll Cardiol, vol.50, pp.1914-1945, 2007.

M. G. Friedrich, U. Sechtem, J. Schulz-menger, G. Holmvang, P. Alakija et al., Cardiovascular magnetic resonance in myocarditis: A JACC White Paper, J Am Coll Cardiol. 28 avr, vol.53, issue.17, pp.1475-87, 2009.

V. M. Ferreira, J. Schulz-menger, G. Holmvang, C. M. Kramer, I. Carbone et al., Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations, J Am Coll Cardiol, vol.18, issue.24, pp.3158-76, 2018.

F. Yang, J. Wang, W. Li, Y. Xu, K. Wan et al., The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis, Eur Radiol. mai, vol.30, issue.5, pp.2616-2642, 2020.

G. D. Aquaro, M. Perfetti, G. Camastra, L. Monti, S. Dellegrottaglie et al., Cardiac MR With Late Gadolinium Enhancement in Acute Myocarditis With Preserved Systolic Function: ITAMY Study, J Am Coll Cardiol, vol.70, issue.16, pp.1977-87, 2017.

M. A. Postow, R. Sidlow, and M. D. Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade, N Engl J Med, vol.11, issue.2, pp.158-68, 2018.

J. S. Weber, F. S. Hodi, J. D. Wolchok, S. L. Topalian, D. Schadendorf et al., Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma, J Clin Oncol. mars, vol.35, issue.7, pp.785-92, 2017.

L. Michel, T. Rassaf, and M. Totzeck, Cardiotoxicity from immune checkpoint inhibitors, Int J Cardiol Heart Vasc. déc, vol.25, p.100420, 2019.

S. S. Mahmood, M. G. Fradley, J. V. Cohen, A. Nohria, K. L. Reynolds et al., Myocarditis in Patients Treated With Immune Checkpoint Inhibitors, J Am Coll Cardiol, vol.24, issue.16, pp.1755-64, 2018.

L. Zhang, M. Awadalla, S. S. Mahmood, A. Nohria, M. Hassan et al., Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis, Eur Heart J, vol.29, issue.2020

D. Y. Wang, J. Salem, J. V. Cohen, S. Chandra, C. Menzer et al., Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Metaanalysis, JAMA Oncol, vol.4, issue.12, pp.1721-1729, 2018.

M. Escudier, J. Cautela, N. Malissen, Y. Ancedy, M. Orabona et al., Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity, Circulation, vol.21, issue.21, pp.2085-2092, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01729764

J. J. Moslehi, J. Salem, J. A. Sosman, B. Lebrun-vignes, and J. Db, Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis, Lancet, vol.10, p.933, 2018.

A. Arbune, A. Soufer, and L. A. Baldassarre, Clinical and Advanced MRI Techniques for Detection of Checkpoint Inhibitor Associated Myocarditis, Curr Cardiovasc Imaging Rep, vol.14, issue.2020, p.3

N. Palaskas, J. Lopez-mattei, J. B. Durand, C. Iliescu, and A. Deswal, Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment, Disponible sur, vol.21

J. R. Brahmer, C. Lacchetti, B. J. Schneider, M. B. Atkins, K. J. Brassil et al., Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy, J Clin Oncol, vol.10, issue.17, pp.1714-68, 2018.

Y. Zhou, Y. Zhu, M. Wang, Y. Xie, C. Chen et al., Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management, Front Pharmacol, vol.29, 2019.

C. Gräni, C. Eichhorn, L. Bière, V. L. Murthy, V. Agarwal et al., Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis, J Am Coll Cardiol, vol.70, issue.16, pp.1964-76, 2017.

L. Zhang, M. Awadalla, S. S. Mahmood, J. D. Groarke, A. Nohria et al., Late Gadolinium Enhancement in Patients with Myocarditis from Immune Checkpoint Inhibitors, J Am Coll Cardiol. 19 mars, vol.73, issue.9, p.675, 2019.

J. A. Luetkens, R. Homsi, A. M. Sprinkart, J. Doerner, D. Dabir et al., Incremental value of quantitative CMR including parametric mapping for the diagnosis of acute myocarditis, Eur Heart J Cardiovasc Imaging. févr, vol.17, issue.2, pp.154-61, 2016.

I. Carbone, H. Childs, A. Aljizeeri, N. Merchant, and M. G. Friedrich, Importance of Reference Muscle Selection in Quantitative Signal Intensity Analysis of T2-Weighted Images of Myocardial Edema Using a T2 Ratio Method, Biomed Res Int, 2015.

A. Esposito, M. Francone, R. Faletti, M. Centonze, F. Cademartiri et al., Lights and shadows of cardiac magnetic resonance imaging in acute myocarditis. Insights Imaging, vol.7, pp.99-110, 2015.

A. M. Maceira, J. V. Monmeneu, B. Igual-muñoz, P. M. Lopez-lereu, P. M. Garcia et al., Reference values for regional and global myocardial T2 mapping with cardiovascular magnetic resonance at 1.5T and 3T, J Cardiovasc Magn Reson. 3 févr, vol.17, issue.1, p.12, 2015.

V. M. Ferreira, S. K. Piechnik, E. Dall'armellina, T. D. Karamitsos, J. M. Francis et al., Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents, J Cardiovasc Magn Reson. 23 mai, vol.16, p.36, 2014.

J. C. Moon, D. R. Messroghli, P. Kellman, S. K. Piechnik, M. D. Robson et al., Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement, J Cardiovasc Magn Reson, vol.15, p.92, 2013.

J. C. Moon, T. A. Treibel, and E. B. Schelbert, T1 mapping for diffuse myocardial fibrosis: a key biomarker in cardiac disease?, J Am Coll Cardiol, vol.62, issue.14, pp.1288-1297, 2013.

V. M. Ferreira, S. K. Piechnik, E. Dall'armellina, T. D. Karamitsos, J. M. Francis et al., T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging, JACC Cardiovasc Imaging, vol.6, issue.10, pp.1048-58, 2013.

P. Haaf, P. Garg, D. R. Messroghli, D. A. Broadbent, J. P. Greenwood et al., Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review, J Cardiovasc Magn Reson, vol.18, issue.1, p.89, 2016.

D. Dabir, N. Child, A. Kalra, T. Rogers, R. Gebker et al., Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study, J Cardiovasc Magn Reson, vol.16, p.69, 2014.

V. M. Ferreira, S. K. Piechnik, E. Dall'armellina, T. D. Karamitsos, J. M. Francis et al., Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance, J Cardiovasc Magn Reson. 21 juin, vol.14, p.42, 2012.

N. Kawel, M. Nacif, A. Zavodni, J. Jones, S. Liu et al., T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region, J Cardiovasc Magn Reson. 1 mai, vol.14, p.27, 2012.

M. Fontana, S. K. White, S. M. Banypersad, D. M. Sado, V. Maestrini et al., Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR, J Cardiovasc Magn Reson. 28 déc, vol.14, p.88, 2012.

D. M. Sado, A. S. Flett, S. M. Banypersad, S. K. White, V. Maestrini et al., Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart, vol.98, pp.1436-1477, 2012.

U. K. Radunski, G. K. Lund, C. Stehning, B. Schnackenburg, S. Bohnen et al., CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging, JACC Cardiovasc Imaging. juill, vol.7, issue.7, pp.667-75, 2014.

C. Gräni, L. Bière, C. Eichhorn, K. Kaneko, V. Agarwal et al., Incremental value of extracellular volume assessment by cardiovascular magnetic resonance imaging in risk stratifying patients with suspected myocarditis, Int J Cardiovasc Imaging. juin, vol.35, issue.6, pp.1067-78, 2019.

A. J. Hauck, D. L. Kearney, and W. D. Edwards, Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error, Mayo Clin Proc, vol.64, issue.10, pp.1235-1280, 1989.

T. Ahmed, A. Goyal, and . Biopsy, Treasure Island (FL): StatPearls Publishing, StatPearls [Internet, 2020.

P. Lurz, C. Luecke, I. Eitel, F. Föhrenbach, C. Frank et al., Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis: The MyoRacer-Trial, J Am Coll Cardiol. 19 avr, vol.67, issue.15, pp.1800-1811, 2016.

B. Marc, P. , O. Benjamin, A. , S. Joe-elie et al., Myocarditis in the Setting of Cancer Therapeutics, Circulation. 2 juill, vol.140, issue.1, pp.80-91, 2019.

D. K. Shakir and K. I. Rasul, Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management, J Clin Med Res. avr, vol.1, issue.1, pp.8-12, 2009.

C. Da, . Cârstea-d, . Zaharie-m, C. B?t?iosu, and . Lungulescu-d, Chemotherapy Related Severe Cardiac Dysfunction -Case Report, Curr Health Sci J, vol.41, issue.4, pp.395-400, 2015.

J. R. Cuomo, G. K. Sharma, P. D. Conger, and N. L. Weintraub, Novel concepts in radiationinduced cardiovascular disease, World J Cardiol. 26 sept, vol.8, issue.9, pp.504-523, 2016.

, Les myocardites aigües immuno-induites (MII) sont des complications rares mais fatales des inhibiteurs des checkpoints immunitaires (ICI), devant faire considérer l'arrêt de l'immunothérapie si confirmée. Les myocardites aigües virales (MV), bien plus fréquentes, n'ont pas cet impact oncologique. L'examen diagnostique non invasif de référence des myocardites aigües

, Le but de cette étude était de comparer les caractéristiques IRM des MII et des MV

. Matériel,

, Le groupe MII comprenait les MA confirmées survenant chez des patients sous ICI et comptait 18 patients (14 hommes ; âge moyen 67 ± 11 ans). Le groupe MV comprenait toutes les autres MA (22 hommes ; âge moyen 35 ± 15 ans). Ces deux groupes ont été analysés sur les paramètres IRMc comprenant notamment les caractéristiques de rehaussement tardif (RT), le T1 mapping natif et après injection ainsi que la fraction de volume extra-cellulaire, MA confirmées selon les critères IRM de Lake-Louise 2018 ont été incluses de mai 2017 à mai 2020 dans cette étude monocentrique rétrospective

, Parmi les 46 patients évalués, la distribution du RT était significativement différent entre les deux groupes avec plus d'atteinte sous-épicardique dans le groupe MV retrouvée chez 27 patients (96%)

, En étude segmentaire, les MV présentaient significativement plus de RT en inféro-latéral (p=0.0001-0.01) alors que les MII atteignaient préférentiellement le septum

L. Mii and . Les, MV se distinguent en terme de distribution et de RT, avec une atteinte préférentiellement inférieure et latérale pour les MV contre septale pour les MII. Les MII présentent plus de RT intra-myocardique que les MV qui

, Mots-clés : myocardite aigüe virale, myocardite aigüe immuno-induite, IRM cardiaque, rehaussement tardif, cartographie mapping